iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, single centre open-label, phase II interventional clinical trial of
combination immunotherapy with Nivolumab and Relatlimab in mCRC.